SEARCH
Search Details
sekizaki tomonori
| Hokkaido University Hospital Internal Medicine Diabetes and Endocrinology | Specially Appointed Assistant Professor |
Researcher basic information
■ URLresearchmap URLホームページURL■ Various IDs
J-Global ID
Research activity information
■ Papers- Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas
Tomonori Sekizaki; Hiraku Kameda; Akinobu Nakamura; Saki Kuwabara; Hiroshi Nomoto; Kyu Yong Cho; Yukitomo Ishi; Hiroaki Motegi; Hideaki Miyoshi; Tatsuya Atsumi
Pituitary, 26, 5, 597, 610, Springer Science and Business Media LLC, 29 Aug. 2023, [Peer-reviewed], [Lead author]
English, Scientific journal - Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study
Tomonori Sekizaki; Hiraku Kameda; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; Kiyohiko Takahashi; Arina Miyoshi; Norio Wada; Jun Takeuchi; So Nagai; Hideaki Miyoshi; Tatsuya Atsumi
Journal of Diabetes Investigation, 12, 11, 1978, 1982, Wiley, 16 Jun. 2021, [Peer-reviewed], [Lead author]
English, Scientific journal, Abstract
Dipeptidyl peptidase‐4 (DPP‐4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP‐4 might affect the immune system. The current multicenter observational case–control study was carried out to investigate the effects of DPP‐4 inhibitor (DPP‐4i) administration on Graves' disease (GD) activity. This study comprised patients with GD and type 2 diabetes, who were administered an oral hypoglycemic agent including DPP‐4i. Exacerbation of GD was defined as an increase of antithyroid drug dose by 6 months after oral hypoglycemic agent administration. A total of 80 patients were enrolled and divided into an exacerbation group or a non‐exacerbation group. The frequency of DPP‐4i administration was significantly higher in the exacerbation group (88%) than that in the non‐exacerbation group (31%). In multivariate logistic regression analysis, there was a significant association between DPP‐4i administration and GD exacerbation (odds ratio 7.39). The current study suggests that DPP‐4i administration is associated with GD exacerbation.
- 細胞株,マウス,患者由来腺腫細胞を用いた,クッシング病に対するニューロメジンB受容体拮抗薬の増殖・ホルモン分泌抑制効果の検討
関崎知紀; 亀田啓; 宮愛香; 野本博司; 曹圭龍; 曹圭龍; 茂木洋晃; 中村昭伸; 三好秀明; 三好秀明; 渥美達也, 日本内分泌学会雑誌, 98, 1, 2022 - ニューロメジンB受容体はACTH産生下垂体腺腫の治療ターゲットとなりうる
関崎知紀; 亀田啓; 中村昭伸; 野本博司; 曹圭龍; 曹圭龍; 伊師雪友; 茂木洋晃; 三好秀明; 三好秀明; 渥美達也, 日本内分泌学会雑誌, 97, 1, 2021 - ニューロメジンB受容体を標的としたACTH産生下垂体腺腫の新規治療法の探索
関崎知紀; 亀田啓; 宮愛香; 野本博司; 曹圭龍; 曹圭龍; 岡本迪成; 茂木洋晃; 中村昭伸; 三好秀明; 三好秀明; 渥美達也, 日本神経内分泌学会学術集会プログラム・抄録集, 47th, 2021 - 常染色体優性多発性嚢胞腎を合併した嚢胞性GH産生下垂体腺腫
桑原咲; 亀田啓; 関崎知紀; 宮愛香; 野本博司; 曹圭龍; 中村昭伸; 岡本迪成; 茂木洋晃; 三好秀明; 三好秀明; 渥美達也, 日本内分泌学会雑誌, 97, 2, 2021 - 減量代謝改善手術後の甲状腺機能の変化
大江悠希; 亀田啓; 関崎知紀; 宮愛香; 野本博司; 曹圭龍; 中村昭伸; 渥美達也; 三好秀明; 三好秀明, 日本内分泌学会雑誌, 97, 5 (Web), 2021 - 肥満糖尿病病態におけるHPA軸の活動性亢進機序
関崎知紀; 亀田啓; 柴山惟; 野本博司; 曹圭龍; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 渥美達也, ACTH Related Peptides (CD-ROM), 31, 2020 - グルコキナーゼ活性化薬の長期投与に伴う血糖降下作用の消失機序の解明
川田晋一朗; 中村昭伸; 山内裕貴; 関崎知紀; 土田和久; 柴山惟; 大森一乃; 高橋清彦; 野本博司; 亀田啓; 曹圭龍; 寺内康夫; 三好秀明; 渥美達也, 糖尿病(Web), 63, Suppl, 2020 - ACTHの一過性上昇後に下垂体性副腎皮質機能低下に至ったニボルマブ誘発性下垂体炎の1例
関崎知紀; 亀田啓; 馬場菜月; 山内裕貴; 平田恵里奈; 柴山惟; 宮野有希恵; 高瀬崇宏; 亀田玲奈; 大場知穂; 曹圭龍; 中村昭伸; 三好秀明; 三好秀明; 大澤崇宏; 篠原信雄; 渥美達也, 日本内分泌学会雑誌, 95, 1, 2019
